BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 28950272)

  • 1. Early Changes of Retinal Morphology in Therapy of Neovascular Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF Agents.
    Enders P; Sitnilska V; Altay L; Fauser S
    Ophthalmologica; 2018; 239(1):45-51. PubMed ID: 28950272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
    Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
    Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
    Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
    Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-vascular endothelial growth factor therapy using SSOCTA.
    Told R; Reiter GS; Mittermüller TJ; Schranz M; Reumueller A; Schlanitz FG; Weigert G; Pollreisz A; Sacu S; Schmidt-Erfurth U
    Acta Ophthalmol; 2021 Mar; 99(2):e240-e246. PubMed ID: 32706171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
    Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset of Retinal Pigment Epithelium Atrophy Subsequent to Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration.
    Sitnilska V; Altay L; Enders P; Hermann M; Muether PS; Fauser S
    Ophthalmologica; 2019; 241(3):154-160. PubMed ID: 30304737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
    Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P
    Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration.
    Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA
    Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
    Kanadani TCM; Dos Reis Veloso CE; Dorairaj S; Nehemy MB
    Ophthalmic Res; 2017; 58(1):18-26. PubMed ID: 28301850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
    Kvannli L; Krohn J
    Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Kanadani TCM; Veloso CE; Nehemy MB
    Ophthalmologica; 2018; 240(4):200-207. PubMed ID: 29768266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term effects of anti-vascular endothelial growth factor on peripapillary choroid and choriocapillaris in eyes with neovascular age-related macular degeneration.
    Lee B; Yoo G; Yun C; Oh J
    Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2163-2172. PubMed ID: 31367847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
    Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G
    Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.
    Karasu B; Gunay BO
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy.
    Farinha C; Santos T; Santos AR; Lopes M; Alves D; Silva R; Cunha-Vaz J
    Retina; 2020 May; 40(5):881-890. PubMed ID: 30689620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHANGES IN EARLY TYPE 3 NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT.
    Miere A; Querques G; Semoun O; Amoroso F; Zambrowski O; Chapron T; Capuano V; Souied EH
    Retina; 2017 Oct; 37(10):1873-1879. PubMed ID: 28079756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
    Chatziralli I; Nicholson L; Vrizidou E; Koutsiouki C; Menon D; Sergentanis TN; Citu MC; Hamilton R; Patel PJ; Hykin P; Sivaprasad S
    Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.